NAD+
Also known as: Nicotinamide Adenine Dinucleotide
Last updated: 1/23/2026 Last reviewed: 1/23/2026
At a Glance
NAD+ (nicotinamide adenine dinucleotide) is a ubiquitous cellular cofactor involved in redox biology and metabolism. Research commonly focuses on NAD+ pathways and modulation via precursors; clinical translation depends on compound, route, and indication.
⚠️ Educational Only: This dossier is an intake stub pending literature curation. It is not medical advice. Protocol/dosing guidance is intentionally not included.
Intake Notes (Unreviewed)
- Tags (from internal sheet): Longevity; Immune system; Cognitive function; Weight Loss; Muscles
- Reported adverse effects (unverified): dizziness; headache; nausea; lab abnormalities (unspecified)
Mechanism of Action (TBD)
Core roles in redox reactions, sirtuins, PARPs, and NAD-consuming enzymes (needs primary sources and clear scope).
Evidence Summary
Low Confidence ReviewLiterature curation pending (including differentiation between NAD+ itself vs precursors such as NR/NMN).
Safety & Unknowns
- Safety and pharmacology differ substantially between NAD+ and various precursors or delivery approaches.
- Reported adverse effects above are unverified and may not be complete.
Regulatory Status
| Region | Status |
|---|---|
| United States (FDA) | Not an approved drug as a general category; context-dependent |
| European Union (EMA) | Context-dependent |
| WADA | Check current list (status may change) |
Changelog
| Date | Change |
|---|---|
| 2026-01-23 | Added intake stub from compounds sheet |